Document is current
Any future updates will be listed below
-
Authors
,
,
Zeggini, Eleftheria https://orcid.org/0000-0003-4238-659X
Mons, Ute
,
Krüger, Janine
von Mutius, Erika
Ziegler, Anette-Gabriele
,
Braun, Anja
Hoffmeister, Michael
Steindorf, Karen
,
Gorski, Stan A.
Landthaler, Markus
Lee, Young-Ae
Schiattarella, Gabriele G.
,
Aziz, N. Ahmad
Breteler, Monique M. B.
Jewell, Sarah
,
Grün, Birgit
Guzman, Carlos A.
Lange, Berit
Leendertz, Fabian H.
,
Hamann, Sandra
Knauthe, Nadja
,
Peters, Annette
- License Information
-
More Information
Article History
First Online: 18 April 2025
Competing interests
: A.-G.Z. declares consulting fees from the Leona M. and Harry B. Helmsley Charitable Trust as a Helmsley T1D Program Ad Hoc Scientific Advisor (June–August 2022) and from Sanofi France, EASD 2024 Medical Symposium (September 2024); honoraria from Georg Thieme Verlag for an article in Diabetes aktuell (“Typ-1-Diabetes: Immuntherapie,” March 2022), from Novo Nordisk Norway for a lecture (“Prediabetes; why and how would we look for it?,” 9 February 2023), from Deutsche Diabetes Gesellschaft for an educational course program lecture (“Pathogenese Typ-1-Diabetes,” November 2023); and Data Monitoring Committee, Data Safety Monitoring Board or Advisory Board memberships for Sanofi France, T1D Screening and Registry Advisory board EASD (October 2023), Sanofi France, Study Advisory Board ISPAD (October 2023), Prevention Bio (Rho) Sanofi, Data Monitoring Committee for clinical trial, Sanofi US Services, Data Monitoring Committee for clinical trial, Sanofi France, Drug Agnostic Strategic Screening Ad Board, ITB-Med, ITB-Med Data Monitoring Committee for clinical trial and Sanofi-Aventis US, Autoimmune T1D Advisory Board at ADA (June 2024). E.v.M. declares membership on the Immune Health Academy Advisory Board of OM Pharma (, Geneva), consultant status for OM Pharma in the field of pediatric pulmonology on the topic “OM-85 in the prevention of respiratory infections on patients’ chronic respiratory disease” and funding from OM Pharma for the BEAR study. All other authors declare no competing interests.
